Granted Patent
B2
US 7,169,898 · App. 10/309,611 · Granted Jan 30, 2007
Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Claims (2)
1. A soluble CD83 protein consisting of amino acid residues 20–145 of SEQ ID NO:2.
2. A soluble CD83 protein consisting of amino acid residues 1 to 130 of SEQ ID NO:8.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2007
From: ALEXANDER STEINKASSERER, PH.D.
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 018854/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 30, 2007
From: STEINKASSERER, ALEXANDER PROF. DR.; LECHMANN, MATTHIAS DR.; ZINSER, DIPL. ING. ELISABETH
To: STEINKASSERER, ALEXANDER, PROFESSOR DR.
Reel/Frame 018828/0532 →
Continuity (1)